Literature DB >> 12586296

Rate of natural disease progression in patients with chronic hepatitis C.

Jean-Pierre Zarski1, John Mc Hutchison, Jean-Pierre Bronowicki, Nathalie Sturm, Richard Garcia-Kennedy, Enkelejda Hodaj, Brenda Truta, Teresa Wright, Robert Gish.   

Abstract

BACKGROUND/AIMS: The interval at which liver biopsy should be repeated in untreated patients with chronic hepatitis C is not defined. We examined fibrosis change by METAVIR scoring in these patients in whom two or more liver biopsies were available.
METHODS: One hundred and eighty patients with histologically proven chronic hepatitis C were studied. Mean delay between biopsies was 3.67+/-2.69 years and 3.08+/-1.43 in the 16 patients having three biopsies. Univariate and multivariate analyses were performed to determine factors associated with liver fibrosis progression.
RESULTS: Median rate of fibrosis progression per year was 0.04 (0.00-0.55) to first biopsy, 0.00 (-0.84-1.02) between first and second biopsy (NS), and 0.17 (0.00-1.50) between second and third biopsy (P<0.05). In multivariate analysis, only age at first biopsy >40 years (OR=5) (2-12) and alcohol consumption of 1-50 g per day (OR=4) (2-12) and more than 50 g per day (OR=8) (3-23) were associated with severe fibrosis. The number of patients who increased in fibrosis stage was significantly higher after 4 years (P<0.02).
CONCLUSIONS: An interval of at least 4-5 years is needed between liver biopsies to measure change in patients with mild liver disease.

Entities:  

Mesh:

Year:  2003        PMID: 12586296     DOI: 10.1016/s0168-8278(02)00387-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  24 in total

1.  Dosimetric Analysis and Normal-Tissue Complication Probability Modeling of Child-Pugh Score and Albumin-Bilirubin Grade Increase After Hepatic Irradiation.

Authors:  Jennifer Pursley; Issam El Naqa; Nina N Sanford; Bridget Noe; Jennifer Y Wo; Christine E Eyler; Matthew Hwang; Kristy K Brock; Beow Y Yeap; John A Wolfgang; Theodore S Hong; Clemens Grassberger
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-04-27       Impact factor: 7.038

Review 2.  Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies.

Authors:  John B Wong
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  Clinical Monitoring of Chronic Hepatitis C Based on its Natural History and Therapy.

Authors:  Douglas L Nguyen; Ke-Qin Hu
Journal:  N Am J Med Sci (Boston)       Date:  2014

Review 4.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

5.  Adequacy of percutaneous non-targeted liver biopsy under real-time ultrasound guidance when comparing the Biopince™ and Achieve™ biopsy needle.

Authors:  Thomas C Hall; Claire Deakin; Gurprit Ss Atwal; Rajeev K Singh
Journal:  Br J Radiol       Date:  2017-10-03       Impact factor: 3.039

Review 6.  Management of HCV in cirrhosis-a rapidly evolving landscape.

Authors:  Suraj A Sharma; Jordan J Feld
Journal:  Curr Gastroenterol Rep       Date:  2015-05

7.  Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C.

Authors:  L Fartoux; A Poujol-Robert; J Guéchot; D Wendum; R Poupon; L Serfaty
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

Review 8.  Management of chronic hepatitis C.

Authors:  V Lo Re; J R Kostman
Journal:  Postgrad Med J       Date:  2005-06       Impact factor: 2.401

9.  Willingness to undergo a repeat liver biopsy among HIV/hepatitis C virus-coinfected and hepatitis C virus-monoinfected patients.

Authors:  Valerianna K Amorosa; Omowunmi Aibana; Norah J Shire; Zachariah Dorey-Stein; Thomas Ferrara; Joanne Gilmore; Jay R Kostman; Vincent Lo Re
Journal:  J Clin Gastroenterol       Date:  2013 May-Jun       Impact factor: 3.062

10.  Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C.

Authors:  Jordi Colmenero; Ramón Bataller; Pau Sancho-Bru; Marlene Domínguez; Montserrat Moreno; Xavier Forns; Miquel Bruguera; Vicente Arroyo; David A Brenner; Pere Ginès
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-07-23       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.